BridgeBio Pharma BBIO 深 滬
交易中 01-28 11:14:11 美东时间
76.14
-1.730
-2.22%
華盛通- 最 高78.35
- 今 開78.35
- 成交量 56.49万股
- 最 低 75.83
- 昨 收 77.87
- 總市值 145.43亿
- 52周最高 81.325
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 28.325
- 委 比 1.33%
- 總股本 1.91亿
- 歷史最高 81.325
- 量 比 0.99
- 振 幅 3.24%
- 歷史最低 4.98
- 每 手 1
- 風險率 14.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UPDATE 2-Intellia gets FDA nod to resume one gene therapy trial after safety pause
UPDATE 2-Intellia gets FDA nod to resume one gene therapy trial after safety pause Updates share movement, adds analyst comment in paragraphs 5 & 8, details in paragraph 6 & 9 By Kamal Choudhury Jan 27 (Reuters) - Intellia Therapeutics NTLA.O said on Tuesday that the U.S. drug regulator has lifted a
01-27 21:29
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced on January 23, 2026, that its compensation committee approved equity grants of 34,199 restricted stock units to 12 new employees. The shares vest quarterly over four years, with 25% vesting on November 16, 2026, and the remainder vesting in equal installments thereafter, contingent on continued employment. These grants were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan, adopted in Novembe...
01-27 21:01
BridgeBio Pharma Announces $550 Million Convertible Senior Notes Offering
BridgeBio Pharma Announces $550 Million Convertible Senior Notes Offering BridgeBio Pharma Inc. has announced a proposed private offering of $550 million aggregate principal amount of convertible senior notes due 2033 to qualified institutional buyers. The company may also grant the initial purchase
01-22 05:08
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
美股盘后 | 泰纳瑞斯钢铁涨3.81%，RELX PLC Sponsored ADR涨3.34%
泰纳瑞斯钢铁涨3.81%；RELX PLC Sponsored ADR涨3.34%；DraftKings, Inc. Class A涨1.75%
01-15 07:11
BridgeBio plans $550M convertible notes offering due 2033
BridgeBio Pharma (BBIO) on Wednesday said it plans to offer $550 million of convertible senior notes due 2033 in a private placement to qualified institutional buyers. The company said it expects to g...
01-15 05:09
BridgeBio Pharma Plans $550M Convertible Notes Offering To Refinance Debt And Strengthen Balance Sheet
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturityPALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.
01-15 05:03
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
<p>BridgeBio Pharma announced plans to issue $550 million in convertible senior notes due 2033 to strengthen its balance sheet, reduce interest expenses, minimize dilution, and extend debt maturity. The proceeds may be used to repurchase or repay a portion of its 2027 notes and for general corporate purposes. The company also plans to use $82.5 million in cash to repurchase common stock, potentially affecting the stock's market price. The final t...
01-14 21:01
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics (BBOT) announced an inducement grant on January 10, 2026, awarding non-qualified stock options to purchase 129,090 shares to an employee hired in December 2025. The exercise price was $13.19 per share, vesting 1/4 on the first anniversary of the employee's start date and in 36 monthly installments thereafter. The grant was made under BBOT’s 2025 Inducement Plan, approved by the board of directors in October 2025, a...
01-13 21:05
BridgeBio Oncology gains outperform rating from Raymond James
Raymond James initiated BridgeBio Oncology Therapeutics (BBOT) at outperform, noting the company is well capitalized and has several phase 1 data readouts this year. The firm set a $24 price target (~...
01-10 04:59
